Two-Year Follow-Up After Transcatheter Aortic Valve Replacement

TAVR remains a good alternative to surgery in high-risk patients, according to the latest data from the PARTNER randomized trial.

In the manufacturer-funded PARTNER trial, transcatheter aortic valve replacement (TAVR) was found to be noninferior to surgical aortic valve replacement at 1 year; symptom improvement was also similar with the two approaches (JW Cardiol June 8 2011). We now have the 2-year results from this randomized trial, which involved 669 high-risk patients with severe aortic stenosis (mean age, 84) in the U.S. who were candidates for surgery.

The two groups had similar cumulative all-cause mortality at 2 years (TAVR, 33.9%; surgery, 35.0%). Although the rate of stroke in the first 30 days had been somewhat higher with TAVR than with surgery (4.6% vs. 2.4%, P=0.12), the raw number of subsequent strokes was similar in the two groups (TAVR, 8; surgery, 12…

Reviewing Author

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Two-Year Follow-Up After Transcatheter Aortic Valve Replacement

Topics

Reviewing Author